Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 14/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29945825 | 1.00 | DYRK1A (0.41) | DYRK1AARPDK2TSHRLMNA | |
| SCHEMBL25983090 | 0.85 | AR (0.46) | ARPDK2TSHRPGR | |
| SCHEMBL21718846 | 0.80 | DYRK1A (0.41) | DYRK1AARPDK2TSHRLMNA | |
| SCHEMBL23726465 | 0.78 | HCAR1 (0.40) | PDK2TSHRLMNAHCAR1 | |
| SCHEMBL1994873 | 0.78 | AR (0.41) | ARPDK2TSHRPGR | |
| SCHEMBL3911267 | 0.78 | AR (0.46) | ARPGR | |
| SCHEMBL29378798 | 0.78 | AR (0.41) | ARPDK2TSHRPGR | |
| SCHEMBL16960191 | 0.76 | AR (0.40) | ARPDK2TSHRPGR | |
| SCHEMBL14699104 | 0.76 | DYRK1A (0.42) | DYRK1AARPDK2TSHRPGR | |
| SCHEMBL5228912 | 0.76 | TSHR (0.54) | ARTSHRPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111153758-B | Method for catalyzing aromatic halogen-containing organic matter dehalogenation by using supported metal oxide | 浙江大学 | 2021-06-08 | — | — | CN | claimed |
| CN-111153758-A | Method for catalyzing aromatic halogen-containing organic matter dehalogenation by using supported metal oxide | 浙江大学 | 2020-05-15 | — | — | CN | claimed |
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4543450-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| EP-4358963-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2023250165-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-111153758-A | Method for catalyzing aromatic halogen-containing organic matter dehalogenation by using supported metal oxide | 浙江大学 | 2020-05-15 | — | — | CN | disclosed |
| CN-106459002-A | Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases | 比奥根MA公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-103687860-B | As P2X7Heterocyclic amide derivatives of receptor antagonists | 埃科特莱茵药品有限公司 | 2016-06-08 | — | — | CN | disclosed |
| EP-2734526-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-9221832-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-12-29 | — | — | US | disclosed |
| US-20140163035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-06-12 | — | — | US | disclosed |
| EP-2734526-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013014587-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-01-31 | — | — | WO | disclosed |
| US-20120101134-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | SOS1, SOS2, SOST | DYRK1A 2401/4885AR 3035/4885PDK2 4472/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | DYRK1A 3243/4885AR 3550/4885PDK2 4051/4885 |
| US-20250059182-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | DYRK1A 2916/4885AR 3254/4885PDK2 4346/4885 |
| US-20140163035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | DYRK1A 1797/4885AR 741/4885PDK2 1373/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | DYRK1A 3243/4885AR 3550/4885PDK2 4051/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | DYRK1A 2916/4885AR 3254/4885PDK2 4346/4885 |
| US-20120101134-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR3 | DYRK1A 2598/4885AR 1563/4885PDK2 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.